Study met primary endpoint demonstrating barzolvolimab’s ability to potently deplete mast cells in the gastrointestinal ...

Results from the Phase II OptiTROP-Lung01 trial (NCT05351788) showed that Sichuan Kelun-Biotech’s sac-TMT combined with ...

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

MIRA Pharmaceuticals (MIRA) announced the completion of the Single Ascending Dose portion of its ongoing Phase 1 clinical trial evaluating oral ...

STOCKHOLM, SE / ACCESS Newswire / August 20, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusin ...

Viking Therapeutics reports positive top-line results from phase 2 VENTURE-Oral Dosing trial of VK2735 tablet formulation in patients with obesity: San Diego Wednesday, August 20, ...

Trethera Corporation ('Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer ...

Pharvaris N.V. ( ($PHVS) ) has released its Q2 earnings. Here is a breakdown of the information Pharvaris N.V. presented to its investors.

RedChip Companies, an international investor relations, media, and research firm focused on microcap and small-cap companies, ...

Access to advanced cancer care is expanding in Norman and south-central Oklahoma with the grand opening of OU Health ...

The platform strategy of using one molecule to target an underlying biological pathway to address many different diseases can ...

A research project has reached an important milestone: the first treatment of an animal tumor with radioactive ion beams has ...